New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
04:55 EDTAZN, AZN, AZN, AZN, AZN, NVS, NVS, NVS, NVS, NVS, THLD, THLD, THLD, THLD, THLD, ABBV, ABBV, ABBV, ABBV, ABBV, RHHBY, RHHBY, RHHBY, RHHBY, RHHBY, JNJ, JNJ, JNJ, JNJ, JNJ, CLSN, CLSN, CLSN, CLSN, CLSN, PFE, PFE, PFE, PFE, PFE, NBS, NBS, NBS, NBS, NBS, INO, INO, INO, INO, INO, CLVS, CLVS, CLVS, CLVS, CLVS, BAYRY, BAYRY, BAYRY, BAYRY, BAYRY, BMY, BMY, BMY, BMY, BMY, MACK, MACK, MACK, MACK, MACKAmerican Society of Clinical Oncology to hold annual meeting
50th Annual Meeting of ASCO is being held in Chicago on May 30-June 3.
News For AZN;BMY;BAYRY;CLVS;INO;NBS;PFE;CLSN;JNJ;RHHBY;ABBV;THLD;NVS;MACK From The Last 14 Days
Check below for free stories on AZN;BMY;BAYRY;CLVS;INO;NBS;PFE;CLSN;JNJ;RHHBY;ABBV;THLD;NVS;MACK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
September 3, 2014
09:15 EDTABBVOn The Fly: Pre-market Movers
Subscribe for More Information
07:59 EDTABBVInfinity Pharmaceuticals to host conference call
Conference call to discuss the strategic collaboration with AbbVie Inc to develop and commercialize duvelisib will be held on September 3 at 8:30 am. Webcast Link
06:48 EDTABBVInfinity, AbbVie announce global strategic collaboration to develop duvelisib
Infinity Pharmaceuticals (INFI) and AbbVie (ABBV) announced that they have entered into a global collaboration to develop and commercialize duvelisib, Infinity’s oral inhibitor of phosphoinositide-3-kinase-delta and PI3K-gamma, for the treatment of patients with cancer. Duvelisib has shown clinical activity across a broad range of blood cancers, including indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia. Infinity is conducting registration-focused trials evaluating the safety and efficacy of duvelisib, including DYNAMOTM, a Phase 2 study in patients with iNHL, and DUOTM, a Phase 3 study in patients with CLL. Under the terms of the agreement, Infinity will receive an upfront payment of $275M and is eligible to receive up to $530M in additional payments for the achievement of development, regulatory and commercial milestones, including up to $405M for the achievement of milestones through the first commercial sale of duvelisib. In the U.S., the companies will jointly commercialize duvelisib and will share equally in any potential profits. Outside the U.S., AbbVie will be responsible for the conduct and funding of commercialization of duvelisib, and Infinity is eligible to receive tiered double-digit royalties on net product sales. Development and commercialization activities under the collaboration will be managed through a shared governance structure. In the U.S., Infinity and AbbVie will jointly commercialize duvelisib, assuming regulatory approval, with Infinity booking sales, and will share equally in any potential profits or losses. Outside the U.S., AbbVie will be responsible for conducting and funding of any commercialization of duvelisib, and Infinity is eligible to receive tiered royalties on net product sales, with percentages ranging from 23.5%-30.5%. For sales of duvelisib in the U.S., AbbVie and Infinity will share equally the existing royalty obligations to Mundipharma International Corporation Limited/Purdue Pharmaceutical Products L.P., and Infinity will be responsible for these royalty obligations outside of the U.S. Infinity will also be responsible for the existing royalty obligations to Millennium: The Takeda Oncology Company for sales of duvelisib worldwide. As part of the strategic collaboration, the companies will share responsibility for the conduct of specific trials specified within an agreed-upon global development plan, with each company leading the development of certain trials within the plan. For the initial global development plan agreed to by the companies, Infinity will fund the trials it conducts and the companies will share equally the funding of trials conducted by AbbVie. The agreement includes plans to launch multiple Phase 2 and Phase 3 studies of duvelisib in hematologic malignancies over the next several years.
06:48 EDTABBVInfinity Pharmaceuticals, AbbVie announce global strategic collaboration
Subscribe for More Information
06:48 EDTRHHBYInfinity Pharmaceuticals partners with Roche for blood cancer clinical studies
Infinity Pharmaceuticals (INFI) has entered into a master clinical supply agreement with Roche (RHHBY) under which Roche will supply Gazyva to Infinity for use in planned clinical studies to evaluate the combination of Gazyva and duvelisib, Infinity’s oral inhibitor of phosphoinositide-3-kinase -delta and PI3K-gamma, in patients with hematologic malignancies, or blood cancers. The companies have also entered into a material transfer agreement under which Infinity is supplying Roche with duvelisib for use in Roche’s preclinical and translational research to evaluate the combination of duvelisib and Gazyva.
05:44 EDTAZNTeva announces positive judgement in patent case against AstraZeneca
Subscribe for More Information
05:43 EDTNVSNovartis Gilenya data redefining MS treatment goals
Novartis announced that new analyses to be presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, MA from September 10-13, will add to the growing evidence confirming the importance of redefining treatment goals in multiple sclerosis, or MS. The goal of MS treatment is to have 'no evidence of disease activity' or 'NEDA', which is currently defined as no evidence of relapses, MRI lesions and disability progression. New data to be presented will reinforce the clinical relevance of brain shrinkage and highlight the benefit of including it as a fourth key measure of MS in the definition of NEDA. In addition, other analyses will show that patients treated with Gilenya were more likely to achieve NEDA based on assessment of these four key measures, including MS-related brain shrinkage, than those on placebo. New Gilenya analyses will show how brain shrinkage is associated with future long-term disability progression in patients with MS and that patients with relapsing MS treated with Gilenya had lower rates of brain shrinkage that importantly were sustained over time. The findings will also provide further evidence of the high efficacy of Gilenya on MS disease activity across four key measures.
September 2, 2014
18:26 EDTCLVSOn The Fly: After Hours Movers
Subscribe for More Information
17:28 EDTNVSNovartis heart drug LCZ696 could drive shares to new highs, Barron's says
Subscribe for More Information
16:25 EDTCLVSClovis to offer $200M of convertible senior notes due 2021 in private placement
15:00 EDTJNJWright Medical hip suit weakness would be buying opportunity, says Brean Capital
Subscribe for More Information
10:29 EDTNVSHigh option volume stocks
Subscribe for More Information
08:18 EDTCLSNCelsion enrolls first patient in its Phase III OPTIMA Study of ThermoDox
Subscribe for More Information
08:07 EDTBAYRYBoston Scientific closed agreement to acquire Interventional business of Bayer
Boston Scientific (BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer (BAYRY). The addition of the Bayer Interventional strong commercial organization and innovative technologies supports the Boston Scientific strategy to provide a comprehensive portfolio of solutions to treat peripheral vascular disease. The transaction includes the leading AngioJet Thrombectomy System and the Fetch 2 Aspiration Catheter, which are used in endovascular procedures to remove blood clots from blocked arteries and veins, and the JetStream Atherectomy System, used in an innovative and fast-growing therapy to remove plaque and thrombi from diseased arteries.
07:59 EDTNVSElbit Imaging subsidiary announces Gamida Cell completed execution of agreements
Subscribe for More Information
07:12 EDTABBV, BMYCredit Suisse names its Top U.S. Pharmaceutical picks for 2H
Subscribe for More Information
07:10 EDTBMYAlder Biopharmaceuticals regains worldwide rights to clazakizumab
Subscribe for More Information
07:01 EDTNVSNovartis volatility expected to move on heart failure drug LCZ696 study
Subscribe for More Information
06:45 EDTAZNAstraZeneca volatility elevated
Subscribe for More Information
06:36 EDTABBVMedtronic, AbbVie reimburse executives for inversion-triggered taxes, WSJ says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use